Toggle Main Menu Toggle Search

Open Access padlockePrints

Granisetron as antiemetic therapy in children with cancer

Lookup NU author(s): Emeritus Professor Alan Craft


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


The safety and efficacy of the new 5HT-3 antagonist granisetron as an antiemetic in children with cancer was evaluated in 40 children at a single doses of 40 mug/kg. No adverse affects attributable to the granisetron were noted. The overall major and complete response rate was 82.5% and this was highest in the younger children. Only 2 patients showed no response. Pharmacokinetic studies showed associations between some pharmacokinetic parameters and age which were no longer apparent after normalisation for body weight. Granisetron is an effective and very well-tolerated antiemetic and appears to be an important addition to the supportive care available for children with cancer. (C) 1995 Wiley-Liss, Inc.

Publication metadata

Author(s): Craft, A. W., Price, L., Eden, O. B., Shaw, P., Campbell, R., Pierce, D. M., Murdoch, R., Upward, J.

Publication type: Article

Publication status: Published

Journal: Medical and Pediatric Oncology

Year: 1995

Volume: 25

Issue: 1

Pages: 28-32

Print publication date: 01/07/1995

ISSN (print): 0098-1532

ISSN (electronic): 1545-5017


DOI: 10.1002/mpo.2950250107

PubMed id: 7752999


Altmetrics provided by Altmetric